Drug reference

Trientine dihydrochloride

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1154

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Wilson’s disease in patients intolerant of penicillamine ▶BY MOUTH USING CAPSULES ▶Adult: 1.2–2.4 g daily in 2–4 divided doses, adjusted according to response, to be taken before food DOSE EQUIVALENCE AND CONVERSION ▶Doses expressed as trientine dihydrochloride. ▶Capsules and tablets are not interchangeable on a milligram-for-milligram basis due to differences in bioavailability. CUPRIOR ® Wilson’s disease in patients intolerant of penicillamine ▶BY MOUTH USING FILM-COATED TABLETS ▶Adult: 450–975 mg daily in 2–4 divided doses, adjusted according to response DOSE EQUIVALENCE AND CONVERSION ▶Each tablet contains trientine tetrahydrochloride equivalent to 150 mg of trientine base; doses expressed as trientine base. ▶Tablets and capsules are not interchangeable on a milligram-for-milligram basis due to differences in bioavailability.

PDF page 1154

Prescribing And Dispensing Information

Trientine is not an alternative to penicillamine for rheumatoid arthritis or cystinuria. Penicillamine-induced systemic lupus erythematosus may not resolve on transfer to trientine. l HANDLING AND STORAGE Manufacturer advises store capsules in a refrigerator (2–8°C)—keep in the original container with the silica gel sachet to protect from moisture.

PDF page 1154

National Funding Access Decisions

Scottish Medicines Consortium (SMC) decisions SMC No. SMC2222 The Scottish Medicines Consortium has advised (November 2019) that trientine tetrahydrochloride (Cuprior ®) is accepted for use within NHS Scotland for the treatment of Wilson’s disease in adults, adolescents and children aged 5 years and older, intolerant to D-penicillamine therapy.

PDF page 1154

Safety

Interactions

→Appendix 1: trientine

PDF page 1154

Side Effects

▶Common or very common Nausea ▶Uncommon Skin reactions ▶Frequency not known Anaemia. gastrointestinal disorders. neurological deterioration in Wilson’s Disease

PDF page 1154

Pregnancy

Teratogenic in animal studies—use only if beneﬁt outweighs risk. Monitoring Monitor maternal and neonatal serum-copper concentrations.

PDF page 1154

Breast Feeding

g Specialist sources indicate caution—limited information available; effect on copper levels in milk conﬂicting and impact on infant unknown. k

PDF page 1154

Dose and formulations

Directions For Administration

CUPRIOR ® Tablets can be divided into 2 equal halves.

PDF page 1154

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 7, 23 ▶Cuprior (GMP-Orphan UK Ltd) Trientine tetrahydrochloride 150 mg Cuprior 150mg tablets | 72 tablet P £2,725.00 Capsule CAUTIONARY AND ADVISORY LABELS 6, 22 ▶Metalite (Imported (Japan)) Trientine dihydrochloride 250 mg Metalite 250mg capsules | 100 capsule P s ▶Trientine dihydrochloride (Non-proprietary) Trientine dihydrochloride 300 mg Trientine dihydrochloride 300mg capsules | 100 capsule P £3,090.00 DT = £3,090.00 Mineral and trace elements deﬁciencies 3.1 Selenium deficiency Selenium deficiency Overview Selenium deﬁciency can occur as a result of inadequate diet or prolonged parenteral nutrition. A selenium supplement should not be given unless there is good evidence of deﬁciency. VITAMINS AND TRACE ELEMENTS

PDF page 1154

Dose text by age group

Adult

1.2–2.4 g daily in 2–4 divided doses, adjusted

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1154

Adult

450–975 mg daily in 2–4 divided doses, adjusted

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1154

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Trientine dihydrochloride

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1154

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 1154

Prescribing And Dispensing Information

PDF page 1154

National Funding Access Decisions

PDF page 1154

Safety

Interactions

→Appendix 1: trientine

PDF page 1154

Side Effects

▶Common or very common Nausea ▶Uncommon Skin reactions ▶Frequency not known Anaemia. gastrointestinal disorders. neurological deterioration in Wilson’s Disease

PDF page 1154

Pregnancy

Teratogenic in animal studies—use only if beneﬁt outweighs risk. Monitoring Monitor maternal and neonatal serum-copper concentrations.

PDF page 1154

Breast Feeding

g Specialist sources indicate caution—limited information available; effect on copper levels in milk conﬂicting and impact on infant unknown. k

PDF page 1154

Dose and formulations

Directions For Administration

CUPRIOR ® Tablets can be divided into 2 equal halves.

PDF page 1154

Medicinal Forms

PDF page 1154

Dose text by age group

Adult

1.2–2.4 g daily in 2–4 divided doses, adjusted

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1154

Adult

450–975 mg daily in 2–4 divided doses, adjusted

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1154

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.